The sales of in Vivo Diagnostic Substances in the US exhibited significant fluctuations from 2013 to 2023. Starting from a high value in 2013, there was a notable drop in 2014, followed by a series of increases and decreases in the subsequent years. The series stood at $1.6691 billion in 2023. Over the last two years, there were minor decreases of 5.84% in 2022 and 1.12% in 2023. The average annual growth rate (CAGR) over the past five years leading up to 2023 was -1.14%.
Future trends to watch for in this market include:
- Continued gradual decline forecasted through 2028.
- Monitoring technological advancements in diagnostic substances.
- Potential regulatory impacts and market adaptation.
